Supporting this study, the use of PRTH-101 (monoclonal anti-DDR1 antibodies) in breast cancer mouse models disrupted stromal collagen organization, increasing immune infiltration and, consequently, survival [100]. The gene discussed is DDR1; the disease is breast carcinoma.